Related references
Note: Only part of the references are listed.Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
Javed Butler et al.
EUROPEAN HEART JOURNAL (2022)
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Muthiah Vaduganathan et al.
LANCET (2022)
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
S. D. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism
Stefan D. Anker et al.
EUROPEAN JOURNAL OF HEART FAILURE (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Estimating lifetime benefits of comprehensive disease -modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
Muthiah Vaduganathan et al.
LANCET (2020)
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial
Francesco Cosentino et al.
CIRCULATION (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
Eri T. Kato et al.
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
S. D. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Racial and Ethnic Disparities in the Utilization of Thrombectomy for Acute Stroke Analysis of Data From 2016 to 2018
Lorenzo Rinaldo et al.
STROKE (2019)
An Update on Racial Disparities With 30-Day Outcomes After Coronary Artery Bypass Graft Under the Affordable Care Act
Brittany N. Burton et al.
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA (2019)
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum
Lars H. Lund et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Racial Disparities in Patient Characteristics and Survival After Acute Myocardial Infarction
Garth N. Graham et al.
JAMA NETWORK OPEN (2018)
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
Karen M. Hallow et al.
DIABETES OBESITY & METABOLISM (2018)
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction
Scott D. Solomon et al.
EUROPEAN HEART JOURNAL (2016)
Racial Disparities in Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stents
Michael A. Gaglia et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)